MISSISSAUGA, ON–(Marketwired – May 24, 2017) – MedX Health Corp. (“MedX”) (TSX VENTURE: MDX) is pleased to announce that it has partnered with OncoTech LLC (“OncoTech”), a US-based company, to develop the market for MedX’s SIAscopy products in Mexico, Colombia and Spain, as well as selected developing countries. OncoTech will immediately begin working on obtaining regulatory approval for SIAscopy in Mexico and Colombia as well as working with its local networks to launch SIAscopy. Since SIAscopy is already CE approved, OncoTech will begin developing a marketing plan for SIAscopy in Spain.
“There is a significant opportunity for MedX’s SIAscopy skin imaging technology in Latin countries, with large populations experiencing significant exposure to the sun and higher incidence of skin cancer,” noted Rob von der Porten, MedX’s CEO. “OncoTech’s experience in marketing medical devices and solutions in these markets, as well as their drive and work ethic, impressed us tremendously. We are delighted to be partnering with OncoTech. The joint marketing partnership leverages our respective strengths into these markets, and will help us establish a meaningful presence faster than we could do on our own.”
“Prevention of both melanoma and non-melanoma skin cancer needs to begin with early detection. MedX’s SIAscopy skin assessment technology will give the vulnerable population in the rural areas of emerging countries such as Mexico and Colombia a unique opportunity to participate in screening and prevention campaigns. We also see business opportunities working with MedX in a number of other countries, including Spain,” stated Frank Melendez, VP of globalization for OncoTech.
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer with its SIAscopy technology. This technology is imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. The devices are sold to physicians and clinics, as well as being deployed in pharmacies and remote clinics from where the images are sent to dermatologists who perform a diagnosis. These products are Health Canada, FDA (US), ARTG and CE approved for use in Canada, the US, Australia, the European Union and Turkey. SIAMETRICS™ is a unique product used in a specialized market for research into the clinical effectiveness of medical treatments of certain skin conditions. MedX also designs, manufactures and distributes quality laser and light therapy technologies for use in numerous medical settings, approved in major jurisdictions, to provide drug free and non-invasive treatment of tissue damage and pain. For more information and a complete profile of MedX and its products visit www.medxhealth.com.
About OncoTech LLC
OncoTech, headquartered in Doral, Florida, is a multidisciplinary organization focused on developing and implementing comprehensive health-care programs using proprietary medical devices primarily through programs directed at vulnerable populations located in rural areas of developing countries, where traditional health-care systems are difficult and complex to implement. OncoTech undertakes projects from inception to commercialization using a predefined product development path they have refined over time. OncoTech is committed to bringing personalized medical technologies to empower people in emerging countries to take control of their family’s health issues. As examples, Oncotech develops educational and self-sampling campaigns to reduce the spread of HPV infections as well as programs to prevent unnecessary death from preventable ailments such as skin cancer and cervical cancer, an example is Human Papilloma Virus (HPV), a precursor of cervical cancer. One of OncoTech’s current products is for self-testing for the HPV virus. OncoTech uses data from DNA analysis to dramatically reduce the needless suffering and death that cervical cancer brings, and to improve health care outcomes in the developing world.
Contacts:
Rob von der Porten
President & CEO
MedX Health Corp
905-670-4428 ext 226
Media Relations
Deborah Thompson
Deborah@dt-communications.ca
416-918-9551